既往接受过结核病治疗的人群中利福平耐药性增加。
Increase in rifampicin resistance among people previously treated for TB.
作者信息
Izudi J, Bajunirwe F, Cattamanchi A
机构信息
Department of Community Health, Mbarara University of Science and Technology, Mbarara, Uganda.
Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
出版信息
Public Health Action. 2023 Mar 21;13(1):4-6. doi: 10.5588/pha.22.0047.
Abstract
People previously treated for TB are at a higher risk of rifampicin-resistant or multidrug-resistant TB (RR/MDR-TB). Uganda's recent RR-TB estimates were not updated, including during the COVID-19 pandemic. Using programmatic data (2012-2021), we report on the distribution and trends in RR-TB among people previously treated for bacteriologically confirmed pulmonary TB (BC-PTB) across six TB clinics in Kampala, Uganda. The RR-TB prevalence between 2012 and 2015 was 0% (95% CI 0-2.3). The prevalence rose significantly in recent years to 7.0% (95% CI 4.4-10.8) between 2016 and 2021 ( < 0.001). RR-TB is increasing among people previously treated for BC-PTB in Kampala; surveillance for RR-TB should be enhanced.
摘要
曾接受过结核病治疗的人患利福平耐药或耐多药结核病（RR/MDR-TB）的风险更高。乌干达最近的RR-TB估计数没有更新，包括在新冠疫情期间。利用规划数据（2012 - 2021年），我们报告了乌干达坎帕拉六家结核病诊所中曾接受过细菌学确诊肺结核（BC-PTB）治疗的人群中RR-TB的分布情况和趋势。2012年至2015年期间RR-TB患病率为0%（95%CI 0 - 2.3）。近年来患病率显著上升，在2016年至2021年期间达到7.0%（95%CI 4.4 - 10.8）（<0.001）。坎帕拉曾接受过BC-PTB治疗的人群中RR-TB正在增加；应加强对RR-TB的监测。
相似文献
1
Increase in rifampicin resistance among people previously treated for TB.既往接受过结核病治疗的人群中利福平耐药性增加。
Public Health Action. 2023 Mar 21;13(1):4-6. doi: 10.5588/pha.22.0047.
2
Surveillance for multi-drug and rifampicin resistant tuberculosis and treatment outcomes among previously treated persons with tuberculosis in the era of GeneXpert in rural eastern Uganda.乌干达东部农村地区在采用GeneXpert技术时代对既往接受过治疗的结核病患者进行耐多药和耐利福平结核病监测及治疗结果分析
J Clin Tuberc Other Mycobact Dis. 2020 Feb 13;19:100153. doi: 10.1016/j.jctube.2020.100153. eCollection 2020 May.
3
Low treatment success rate among previously treated persons with drug-susceptible pulmonary tuberculosis in Kampala, Uganda.乌干达坎帕拉先前接受治疗的药物敏感型肺结核患者的治疗成功率较低。
J Clin Tuberc Other Mycobact Dis. 2023 May 12;32:100375. doi: 10.1016/j.jctube.2023.100375. eCollection 2023 Aug.
4
Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.Xpert MTB/RIF对从复治肺结核患者中筛查出的耐多药或利福平耐药结核病治疗效果的前瞻性队列研究。
Ann Palliat Med. 2020 Mar;9(2):239-246. doi: 10.21037/apm.2020.02.17. Epub 2020 Mar 17.
5
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.用于检测成人肺结核和利福平耐药性的Xpert® MTB/RIF检测
Cochrane Database Syst Rev. 2013 Jan 31(1):CD009593. doi: 10.1002/14651858.CD009593.pub2.
6
Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.导致结核患者中耐多药/利福平耐药率高的因素：来自俄罗斯哈巴罗夫斯克边疆区的一项流行病学横断面和定性研究。
BMC Infect Dis. 2022 Jul 13;22(1):612. doi: 10.1186/s12879-022-07598-7.
7
Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia.埃塞俄比亚亚的斯亚贝巴涂片阴性疑似肺结核患者中结核病、耐多药结核病及相关危险因素的流行情况。
BMC Infect Dis. 2019 Jul 19;19(1):641. doi: 10.1186/s12879-019-4241-7.
8
Tuberculosis risk factors among tuberculosis patients in Kampala, Uganda: implications for tuberculosis control.乌干达坎帕拉的结核病患者的结核病风险因素：对结核病控制的影响。
BMC Public Health. 2015 Jan 21;15:13. doi: 10.1186/s12889-015-1376-3.
9
Chest X-ray findings in drug-sensitive and drug-resistant pulmonary tuberculosis patients in Uganda.乌干达药物敏感和耐药肺结核患者的胸部X光检查结果
J Clin Tuberc Other Mycobact Dis. 2022 Mar 25;27:100312. doi: 10.1016/j.jctube.2022.100312. eCollection 2022 May.
10
Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.2007 年至 2013 年中国耐多药结核分枝杆菌分离株中莫西沙星耐药率的大幅增加。
Microbiol Spectr. 2021 Dec 22;9(3):e0040921. doi: 10.1128/Spectrum.00409-21. Epub 2021 Dec 1.
引用本文的文献
1
Removal of Rifampicin and Rifaximin Antibiotics on PET Fibers: Optimization, Modeling, and Mechanism Insight.去除PET纤维上的利福平及利福昔明抗生素：优化、建模及作用机制洞察
Polymers (Basel). 2025 Jul 30;17(15):2089. doi: 10.3390/polym17152089.
2
Prevalence of Drug-Resistant Tuberculosis in HIV-Positive and Diabetic Patients in Sinaloa, Mexico: A Retrospective Cross-Sectional Study.墨西哥锡那罗亚州艾滋病毒阳性和糖尿病患者中耐多药结核病的患病率：一项回顾性横断面研究
Trop Med Infect Dis. 2024 Apr 22;9(4):89. doi: 10.3390/tropicalmed9040089.
3
Negative effects of undernutrition on sputum smear conversion and treatment success among retreatment cases in Uganda: A quasi-experimental study.营养不良对乌干达复治病例痰涂片转阴及治疗成功的负面影响：一项准实验研究。
J Clin Tuberc Other Mycobact Dis. 2024 Feb 24;35:100422. doi: 10.1016/j.jctube.2024.100422. eCollection 2024 May.
4
Risk factors for unsuppressed viral load after intensive adherence counseling among HIV infected persons in Kampala, Uganda: a nested case-control study.乌干达坎帕拉感染艾滋病毒人群强化依从性咨询后病毒载量未受抑制的风险因素：巢式病例对照研究。
AIDS Res Ther. 2023 Dec 19;20(1):90. doi: 10.1186/s12981-023-00583-3.
本文引用的文献
1
Effect of 6-month vs. 8-month regimen on retreatment success for pulmonary TB.6个月疗程与8个月疗程对肺结核再治疗成功率的影响。
Int J Tuberc Lung Dis. 2022 Dec 1;26(12):1188-1190. doi: 10.5588/ijtld.22.0357.
2
Readiness to implement on-site molecular testing for tuberculosis in community health centers in Uganda.乌干达社区卫生中心实施结核病现场分子检测的准备情况。
Implement Sci Commun. 2022 Feb 2;3(1):9. doi: 10.1186/s43058-022-00260-y.
3
Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.乌干达西南部诊断为肺结核的患者中利福平及异烟肼耐药情况。
PLoS One. 2021 Oct 29;16(10):e0259221. doi: 10.1371/journal.pone.0259221. eCollection 2021.
4
Epidemiological profile of patients with rifampicin-resistant tuberculosis: an analysis of the Uganda National Tuberculosis Reference Laboratory Surveillance Data, 2014-2018.利福平耐药结核病患者的流行病学特征：乌干达国家结核病参考实验室监测数据的分析，2014-2018 年。
Antimicrob Resist Infect Control. 2021 May 8;10(1):76. doi: 10.1186/s13756-021-00947-2.
5
Rifampicin resistance among Mycobacterium tuberculosis-infected individuals using GeneXpert MTB/RIF ultra: a hospital-based study.GeneXpert MTB/RIF ultra 检测结核分枝杆菌感染人群中的利福平耐药情况：一项基于医院的研究。
Trop Med Int Health. 2021 Feb;26(2):159-165. doi: 10.1111/tmi.13489. Epub 2020 Nov 27.
6
High Prevalence of Rifampicin Resistance Associated with Rural Residence and Very Low Bacillary Load among TB/HIV-Coinfected Patients at the National Tuberculosis Treatment Center in Uganda.乌干达国家结核病治疗中心结核/艾滋病毒合并感染患者中农村居住与极低细菌载量与利福平耐药高度相关。
Biomed Res Int. 2020 Jul 25;2020:2508283. doi: 10.1155/2020/2508283. eCollection 2020.
7
Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study.埃塞俄比亚德布雷马科斯转诊医院疑似结核病患者中结核分枝杆菌的利福平耐药模式及相关因素：一项横断面研究
BMC Res Notes. 2017 Jan 3;10(1):8. doi: 10.1186/s13104-016-2328-4.
Zotero 插件